HITlights: A career perspective on heparin-induced thrombocytopenia

American Journal of Hematology

Volumn 87, Issue SUPPL. 1, 2012, Pages

  Warkentin, Theodore E ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FONDAPARINUX; HEPARIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LOW MOLECULAR WEIGHT HEPARIN; THROMBOCYTE FACTOR 4;

ANAPHYLAXIS; ARTERY THROMBOSIS; ARTICLE; BODY MASS; CENTRAL VENOUS CATHETER; DEEP VEIN THROMBOSIS; DIAGNOSTIC ERROR; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG REEXPOSURE; ENZYME IMMUNOASSAY; GANGRENE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERCOAGULABILITY; LUNG EMBOLISM; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RISK FACTOR; STOICHIOMETRY; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; TREATMENT FAILURE; VEIN THROMBOSIS;

ANTICOAGULANTS; AUTOANTIBODIES; HEPARIN; PLATELET ACTIVATION; PLATELET COUNT; PLATELET FACTOR 4; SEROTONIN; THROMBOCYTOPENIA; VENOUS THROMBOSIS;

EID: 84859986070     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23127     Document Type: Article

References (100)

1. Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. Annu Rev Med 1989; 40: 31-44.
2. Parkinson D, Warkentin TE, Jell RM. Spinal-cord concussion in frogs: A study of reflex changes. Surg Neurol 1983; 20: 456-460.
3. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67: 27-30.
4. Bell WR. Heparin-associated thrombocytopenia and thrombosis. J Lab Clin Med 1988; 111: 600-605.
5. Warkentin TE, Hayward CPM, Smith CA, et al. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med 1992; 120: 371-379.
6. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: Towards consensus. Thromb Haemost 1998; 79: 1-7.
7. Warkentin TE, Greinacher A, Gruel Y, Aster RH, Chong BH, on behalf of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Laboratory testing for heparin-induced thrombocytopenia: A conceptual framework and implications for diagnosis. J Thromb Haemost 2011; 9: 2498-2500.
8. Kelton JG, Smith JW, Warkentin TE, et al. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994; 83: 3232-3239.
9. Greinacher A, Pötzsch B, Amiral J, et al. Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994; 71: 247-251.
10. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia: Thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93: 81-88.
11. Horsewood P, Warkentin TE, Hayward CPM, Kelton JG. The epitope specificity of heparin-induced thrombocytopenia. Br J Haematol 1996; 95: 161-167.
12. Levine MN, Hirsh J, Gent M, et al. Prevention of deep vein thrombosis after elective hip surgery: A randomized trial comparing glow molecular weight heparin with standard unfractionated heparin. Ann Intern Med 1991; 114: 545-551.
13. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335.
14. Warkentin TE, Sheppard JI, Horsewood P, et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000; 96: 1703-1708.
15. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003; 163: 2518-2524.
16. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: A nested cohort study. Chest 2005; 127: 1857-1861.
17. Warkentin TE, Sheppard JI, Moore JC, et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: How much class do we need? J Lab Clin Med 2005; 146: 341-346.
18. Warkentin TE, Sheppard JI, Moore JC, et al. Studies of the immune response in heparin-induced thrombocytopenia. Blood 2009; 113: 4963-4969.
19. Lindhoff-Last E, Gerdsen F, Ackermann H, Bauersachs R. Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. Br J Haematol 2001; 113: 886-890.
20. Warkentin TE, Sheppard JI, Moore JC, et al. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 2008; 6: 1304-1312.
21. Warkentin TE, Sheppard JI, Moore JC, Kelton JG. The use of well-characterized sera for the assessment of new diagnostic enzyme-immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2010; 8: 216-218.
22. Warkentin TE, Smith JW. The alloimmune thrombocytopenic syndromes. Transfus Med Rev 1997; 11: 296-307.
23. Warner MN, Moore JC, Warkentin TE, et al. A prospective study of protein-specific assays used to investigate idiopathic thrombocytopenic purpura. Br J Haematol 1999; 104: 442-447.
24. Warkentin TE. Drug-induced immune-mediated thrombocytopenia-From purpura to thrombosis. N Engl J Med 2007; 356: 891-893.
25. Warkentin TE, Hayward CPM, Kelton JG. High frequency and wide clinical spectrum of clinical sequelae in heparin-induced thrombocytopenia. Blood 1991; 78 (Suppl 1): 343a.
26. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996; 101: 502-507.
27. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344: 1286-1292.
28. Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep 2003; 2: 148-157.
29. Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006; 4: 759-765.
30. Warkentin TE, Linkins LA. Non-necrotizing heparin-induced skin lesions and the 4T's score. J Thromb Haemost 2010; 8: 1483-1485.
31. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: Recognition, treatment, and prevention. The Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 311S-337S.
32. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133: 340S-380S.
33. Hartman V, Malbrain M, Daelemans R, et al. Pseudo-pulmonary embolism as a sign of acute heparin-induced thrombocytopenia in hemodialysis patients: Safety of resuming heparin after disappearance of HIT antibodies. Nephron Clin Pract 2006; 104: c143-c148.
34. Wanaka K, Matsuo T, Matsuo M, et al. Re-exposure to heparin in uremic patients requiring hemodialysis with heparin-induced thrombocytopenia. J Thromb Haemost 2010; 8: 616-618.
35. Warkentin TE. Heparin-induced thrombocytopenia: Pathogenesis and management. Br J Haematol 2003; 121: 535-555.
36. Warkentin TE, Soutar RL, Panju A, Ginsberg JS. Acute systemic reactions to intravenous bolus heparin therapy: Characterization and relationship to heparin-induced thrombocytopenia [Abstract]. Blood 1992; 80 (Suppl 1): 160a.
37. Warkentin TE, Greinacher A. Heparin-induced anaphylactic and anaphylactoid reactions: Two distinct but overlapping syndromes. Expert Opin Drug Saf 2009; 8: 129-144.
38. Hillis C, Warkentin TE, Taha K, Eikelboom JW. Chills and limb pain following administration of low-molecular-weight heparin for treatment of acute venous thromboembolism. Am J Hematol 2011; 86: 603-606.
39. Warkentin TE, Hirte HW, Anderson DR, et al. Transient global amnesia associated with acute heparin-induced thrombocytopenia. Am J Med 1994; 97: 489-491.
40. Teh CH, Robertson MN, Warkentin TE, et al. Transient global amnesia as the presenting feature of heparin-induced thrombocytopenia. J Card Surg 2010; 25: 300-302.
41. Warkentin TE. Heparin-induced skin lesions. Br J Haematol 1996; 92: 494-497.
42. Warkentin TE. Heparin-induced thrombocytopenia. Curr Hematol Rep 2002; 1: 63-72.
43. Warkentin TE. Think of HIT. Hematol Am Soc Hematol Educ Program 2006; 408-414.
44. Linkins LA, Warkentin TE. Heparin-induced thrombocytopenia: Real world issues. Semin Thromb Hemost 2011; 37: 653-663.
45. Warkentin TE, Bernstein RA. Delayed-onset heparin-induced thrombocytopenia and cerebral thrombosis after a single administration of unfractionated heparin. N Engl J Med 2003; 348: 1067-1069.
46. Refaai MA, Warkentin TE, Axelson M, et al. Delayed-onset heparin-induced thrombocytopenia, venous thromboembolism, and cerebral venous thrombosis: A consequence of heparin "flushes." Thromb Haemost 2007; 98: 1139-1140.
47. Hong AP, Cook DJ, Sigouin CS, Warkentin TE. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood 2003; 101: 3049-3051.
48. Warkentin TE, Cook DJ. Current perspective of venous thrombosis in the upper extremity: A rebuttal. J Thromb Haemost 2009; 7: 237-238.
49. Warkentin TE, Sheppard JI. Clinical sample investigation (CSI) hematology: Pinpointing the precise onset of heparin-induced thrombocytopenia (HIT). J Thromb Haemost 2007; 5: 636-637.
50. Linkins LA, Warkentin TE. The approach to heparin-induced thrombocytopenia. Semin Respir Crit Care Med 2008; 29: 66-74.
51. Warkentin TE, Elavathil LJ, Hayward CPM, et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997; 127: 804-812.
52. Smythe MA, Warkentin TE, Stephens JL, et al. Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. Am J Hematol 2002; 71: 50-52.
53. Warkentin TE. Should vitamin K be administered when HIT is diagnosed after administration of coumarin? J Thromb Haemost 2006; 4: 894-896.
54. Srinivasan AF, Rice L, Bartholomew JR, et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Ann Intern Med 2004; 164: 66-70.
55. Warkentin TE. Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. Transfus Med Rev 1996; 10: 249-258.
56. Warkentin TE. Venous limb gangrene during warfarin treatment of cancer-associated deep venous thrombosis. Ann Intern Med 2001; 135: 589-593.
57. Warkentin TE, Sarode R, Johnston MA, Crowther MA. The pathogenesis of warfarin-associated venous limb ischemia and gangrene complicating cancer: Clinical and laboratory parallels with heparin-induced thrombocytopenia (HIT) [Abstract]. Thromb Res, in press.
58. Warkentin TE, Hayward CPM, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994; 84: 3691-3699.
59. Warkentin TE, Sheppard JI. Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: A comparison with standard platelet agonists. Platelets 1999; 10: 319-326.
60. Hughes M, Hayward CPM, Warkentin TE, et al. Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. Blood 2000; 96: 188-194.
61. Rauova L, Hirsch JD, Greene TK, et al. Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia. Blood 2010; 116: 5021-5131.
62. Warkentin TE. An overview of the heparin-induced thrombocytopenia syndrome. Semin Thromb Hemost 2004; 30: 273-283.
63. Warkentin TE. Agents for the treatment of heparin-induced thrombocytopenia. Hematol Oncol Clin N Am 2010; 24: 755-775.
64. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-Induced Thrombocytopenia, 4th ed. New York: Informa Healthcare; 2007. pp 21-66.
65. Greinacher A, Warkentin TE. The direct thrombin inhibitor hirudin. Thromb Haemost 2008; 99: 819-829.
66. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001; 135: 502-506.
67. Alsaleh KA, Al-Nasser SM, Bates SM, et al. Delayed-onset heparin-induced thrombocytopenia caused by low-molecular-weight heparin manifesting during fondaparinux prophylaxis. Am J Hematol 2008; 83: 876-878.
68. Rice L, Attisha WK, Drexler A, Francis JL. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med 2002; 136: 210-215.
69. Prechel MM, McDonald MK, Jeske WP, et al. Activation of platelets by heparin-induced thrombocytopenia antibodies in the serotonin release assay is not dependent on the presence of heparin. J Thromb Haemost 2005; 3: 2168-2175.
70. Socher I, Kroll H, Jorks S, et al. Heparin-independent activation of platelets by heparin-induced thrombocytopenia antibodies: A common occurrence. J Thromb Haemost 2008; 6: 197-200.
71. Warkentin TE, Davidson BL, Büller HR, et al. Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE. Chest 2011; 140: 366-373.
72. Lee DH, Warkentin TE. Frequency of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-Induced Thrombocytopenia, 4th ed. New York: Informa Healthcare; 2007. pp 67-116.
73. Warkentin TE, Sheppard JI, Sigouin CS, et al. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 2006; 108: 2937-2941.
74. Warkentin TE, Cook RJ, Marder VJ, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005; 106: 3791-3796.
75. Lubenow N, Hinz P, Thomaschewski S, et al. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood 2010; 115: 1797-1803.
76. Greinacher A, Warkentin TE. Contaminated heparin. N Engl J Med 2008; 359: 1291-1292.
77. Warkentin TE, Cook RJ, Marder VJ, Greinacher A. Anti-PF4/heparin antibody formation post-orthopedic surgery thromboprophylaxis: The role of non-drug risk factors and evidence for a stoichiometry-based model of immunization. J Thromb Haemost 2010; 8: 504-512.
78. Greinacher A, Alban S, Omer-Adam MA, et al. Heparin-induced thrombocytopenia: A stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. Thromb Res 2008; 122: 211-220.
79. Warkentin TE. HIT treatment easier, HIT prevention harder. Blood, in press.
80. Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007; 356: 2653-2654.
81. Salem M, Elrefai S, Shrit MA, Warkentin TE. Fondaparinux thromboprophylaxis-associated heparin-induced thrombocytopenia syndrome complicated by arterial thrombotic stroke. Thromb Haemost 2010; 104: 1071-1072.
82. Warkentin TE. Fondaparinux: Does it cause HIT? Can it treat HIT? Exp Rev Hematol 2010; 3: 567-581.
83. Jay RM, Warkentin TE. Fatal heparin-induced thrombocytopenia (HIT) during warfarin thromboprophylaxis following orthopedic surgery: Another example of "spontaneous" HIT? J Thromb Haemost 2008; 6: 1598-1600.
84. Pruthi RK, Daniels PR, Nambudiri GS, Warkentin TE. Heparin-induced thrombocytopenia (HIT) during postoperative warfarin thromboprophylaxis: A second example of postorthopedic surgery "spontaneous" HIT? J Thromb Haemost 2009; 7: 499-501.
85. Warkentin TE, Makris M, Jay RM, Kelton JG. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. Am J Med 2008; 121: 632-636.
86. Krauel K, Pötschke C, Weber C, et al. Platelet factor 4 binds to bacteria, inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood 2011; 117: 1370-1378.
87. Greinacher A, Holtfreter B, Krauel K, et al. Association of natural anti-platelet factor 4/heparin antibodies with periodontal disease. Blood 2011; 118: 1395-1401.
88. Greinacher A, Kohlmann T, Strobel U, et al. The temporal profile of the anti-PF4/heparin immune response. Blood 2009; 113: 4970-4976.
89. Lo GK, Sigouin CS, Warkentin TE. What is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol 2007; 82: 1037-1043.
90. Whitlatch NL, Kong DF, Metjian AD, et al. Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia. Blood 2010; 116: 1761-1766.
91. Althaus K, Strobel U, Warkentin TE, Greinacher A. Combined use of the high heparin step and optical density to optimize diagnostic sensitivity and specificity of an anti-PF4/heparin enzyme-immunoassay. Thromb Res 2011; 128: 256-260.
92. Warkentin TE, Sheppard JI. No significant improvement in diagnostic specificity of an anti-PF4/polyanion immunoassay with use of high heparin confirmatory procedure. J Thromb Haemost 2006; 4: 281-282.
93. Warkentin TE. Heparin-induced thrombocytopenia in critically ill patients. Crit Care Clin 2011; 27; 805-823.
94. Selleng S, Malowsky B, Strobel U, et al. Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia even when antibody tests are positive. J Thromb Haemost 2010; 8: 30-36.
95. Smythe MA, Warkentin TE, Woodhouse AL, Zakalik D. Venous limb gangrene and fatal hemorrhage: Adverse consequences of HIT "overdiagnosis" in a patient with antiphospholipid syndrome. Am J Hematol 2011; 86: 188-191.
96. Lubenow N, Warkentin TE, Greinacher A, et al. Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s. Thromb Res 2006; 117: 507-515.
97. Warkentin TE, Pai M, Sheppard JI, Schulman S, Spyropoulos AC, Eikelboom JW. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: A 30-month, 16-patient case series. J Thromb Haemost 2011; 9: 2389-2396.
98. Goldfarb MJ, Blostein MD. Fondaparinux in acute heparin-induced thrombocytopenia: A case series. J Thromb Haemost 2011; 9: 2501-2503.
99. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007; 357: 1903-1915.
100. Kelton JG, Warkentin TE. Heparin-induced thrombocytopenia: A historical perspective. Blood 2008; 112: 2607-2616.